141,972 Shares in BridgeBio Pharma, Inc. (NASDAQ:BBIO) Bought by Tema Etfs LLC

Tema Etfs LLC acquired a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 141,972 shares of the company's stock, valued at approximately $3,896,000. BridgeBio Pharma makes up about 1.6% of Tema Etfs LLC's portfolio, making the stock its 23rd largest position. Tema Etfs LLC owned approximately 0.08% of BridgeBio Pharma at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Steward Partners Investment Advisory LLC lifted its holdings in BridgeBio Pharma by 85.8% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company's stock valued at $28,000 after acquiring an additional 472 shares during the period. Itau Unibanco Holding S.A. bought a new stake in BridgeBio Pharma during the 4th quarter valued at approximately $41,000. Sterling Capital Management LLC lifted its holdings in shares of BridgeBio Pharma by 554.6% in the fourth quarter. Sterling Capital Management LLC now owns 1,787 shares of the company's stock worth $49,000 after buying an additional 1,514 shares in the last quarter. Avanza Fonder AB purchased a new position in shares of BridgeBio Pharma during the fourth quarter valued at about $181,000. Finally, First Bank & Trust purchased a new stake in shares of BridgeBio Pharma during the 4th quarter worth approximately $205,000. 99.85% of the stock is currently owned by institutional investors.

BridgeBio Pharma Stock Performance

Shares of BBIO traded down $0.13 during trading hours on Friday, hitting $32.84. The stock had a trading volume of 715,824 shares, compared to its average volume of 2,431,658. BridgeBio Pharma, Inc. has a 12-month low of $21.62 and a 12-month high of $39.54. The company's fifty day simple moving average is $34.47 and its 200 day simple moving average is $31.78. The firm has a market cap of $6.24 billion, a P/E ratio of -11.52 and a beta of 1.15.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The company reported ($0.88) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.12. The company had revenue of $36.74 million for the quarter, compared to analyst estimates of $57.14 million. The business's revenue was down 44.8% on a year-over-year basis. During the same period last year, the firm posted ($0.20) earnings per share. As a group, sell-side analysts predict that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current fiscal year.

Analyst Ratings Changes

BBIO has been the subject of a number of research analyst reports. Citigroup lifted their price objective on shares of BridgeBio Pharma from $45.00 to $49.00 and gave the company a "buy" rating in a report on Friday, February 21st. Piper Sandler boosted their price objective on shares of BridgeBio Pharma from $46.00 to $63.00 and gave the company an "overweight" rating in a report on Wednesday, April 30th. Scotiabank upped their target price on BridgeBio Pharma from $52.00 to $55.00 and gave the stock a "sector outperform" rating in a research note on Wednesday, April 30th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $95.00 price target on shares of BridgeBio Pharma in a report on Friday, February 21st. Finally, UBS Group increased their target price on BridgeBio Pharma from $65.00 to $72.00 and gave the company a "buy" rating in a report on Wednesday, April 30th. One research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $57.09.

Insider Activity at BridgeBio Pharma

In other BridgeBio Pharma news, CAO Maricel Apuli sold 1,026 shares of the company's stock in a transaction that occurred on Friday, May 2nd. The stock was sold at an average price of $38.51, for a total value of $39,511.26. Following the completion of the sale, the chief accounting officer now directly owns 147,639 shares in the company, valued at $5,685,577.89. This represents a 0.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Neil Kumar sold 75,000 shares of BridgeBio Pharma stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $33.57, for a total value of $2,517,750.00. Following the transaction, the chief executive officer now directly owns 5,023,447 shares in the company, valued at approximately $168,637,115.79. The trade was a 1.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 12,475,682 shares of company stock valued at $419,721,156 over the last three months. 18.20% of the stock is owned by insiders.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.